Prologue Medicines
↗Belmont, USA
Prologue Medicines is a biotechnology company focused on unlocking the therapeutic potential of the viral proteome. By leveraging its proprietary DELVE™ (Decoding Evolutionary Logic of Variant Ensembles) platform, the company uses machine learning and high-throughput biology to identify viral proteins that can modulate human physiology, aiming to create programmable medicines for a wide range of diseases.
Founded by Flagship Pioneering, the company operates as a bioplatform innovation startup. It aims to expand the functional boundaries of human proteins by co-opting viral evolution, with an initial therapeutic focus on immunology, oncology, and metabolic disorders.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2023
Ownership:private
Status:operating
FUNDING
Stage:Series C
Total Raised:$50M
Investors:Flagship Pioneering
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery
Modalities:Biologics, Protein therapeutics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Flagship Pioneering (Founder/Investor)
COMPETITION
Position:Emerging
Competitors:CStone Pharma, Topas Therapeutics, Enlaza
LEADERSHIP
Key Executives:
Lovisa Afzelius - Co-Founder and CEO
Theonie Anastassiadis - Founding President
Hozefa Bandukwala - Founding Chief Scientific Officer
Scientific Founders:Lovisa Afzelius, Hozefa Bandukwala
LINKS
Website:prologuemedicines.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Prologue Medicines and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Prologue Medicines. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.